Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07543991

Intraneural Administration of scAAV9/JeT-GAN Into the Vagus Nerve for Patients With Giant Axonal Neuropathy (GAN)

Giant axonal neuropathy (GAN) is a rare pediatric disorder caused by autosomal recessive mutations in the GAN gene. GAN is a multisystem, neurodegenerative disorder affecting the peripheral nervous system (PNS), central nervous system (CNS) and autonomic nervous system (ANS).

GAN is a fatal disease with many patients not surviving past early adulthood due to aspiration pneumonia and pulmonary complications. Currently, there are no approved drugs or other therapies for the treatment of GAN; and only supportive care therapies exist, leaving an unmet medical need to treat this rare, progressive, and ultimately fatal neurodegenerative disease.

The drug used in this study (scAAV9/JeT-GAN) has been studied in a previous gene therapy clinical trial by which the drug was administered as a single injection into the spinal canal (intrathecal [IT] administration) to treat the symptoms associated with the CNS and PNS neurodegeneration; however, this administration method did not address the symptoms associated with neurodegeneration of the ANS.

To treat the symptoms associated with ANS, this study has been designed to evaluate the safety and tolerability of a single dose of scAAV9/JeT-GAN administered directly into the left vagus nerve (intraneurally) in participants who have previously received scAAV9/JeT-GAN administered intrathecally.

This study involves the use of an investigational drug called scAAV9/JeT-GAN "Investigational" means that the drug has not been approved by the U.S. Food & Drug Administration (FDA) for the treatment of GAN and the progression of neurodegeneration to the CNS, PNS and ANS.

This is the first study in humans to administer the drug directly into the left vagus nerve. We want to find out what effects, good and/or bad, scAAV9/JeT-GAN has when administered directly into the vagus nerve.

The safety of intrathecal (IT) administration of scAAV9/JeT-GAN has been established in a prior research study; however, the people in this study will be the first people to receive the drug intraneurally. As a result, information about the safety and effectiveness of the route of administration is incomplete and all of the possible side effects are not yet known.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Giant Axonal Neuropathy (GAN) Congenital Abnormalities Congenital, Hereditary, and Neonatal Diseases and Abnormalities Genetic Diseases, Inborn Giant Axonal Neuropathy Hereditary Sensory and Motor Neuropathy Heredodegenerative Disorders, Nervous System Nervous System Diseases Nervous System Malformations Neurodegenerative Diseases Neuromuscular Diseases Peripheral Nervous System Diseases Polyneuropathies

Age range

10 year–25 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

Primary location

Children's Health

Dallas, Texas, 75235, United States

Location status: Recruiting

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Confirmed diagnosis of GAN disease by:
  • Genomic DNA mutation analysis demonstrating homozygous or compound heterozygous, pathogenic and/or confirmed pathogenic variants in the GAN gene;
  • Clinical history or symptoms to ANS dysfunction.
  • Previously treated with IT AAV/GAN and completion of 5 year follow up prior to enrollment.
  • Parents/l LAR willing to accompany the participant to all study visits and who will provide consent for their child's participation.
  • Subject able to comply with all protocol requirements and procedures.
  • Up to date on childhood vaccinations according to Centers for Disease Control (CDC) guidelines. Annual influenza and COVID-19 vaccinations are highly recommended.
  • Female participants of child-bearing potential must have a negative urine and/or negative serum pregnancy test at screening/baseline; (a) Female participants must agree to use an effective form of birth control during study participation.

Exclusion criteria

  • Inability to participate in study procedures (as determined by the site investigator).
  • Inability to be safely sedated in the opinion of the clinical anesthesiologist.
  • Concomitant illness or requirement for chronic drug treatment that in the opinion of the Principal Investigator (PI) creates unnecessary risks for gene transfer.
  • The presence of significant non-GAN related CNS impairment or behavioral disturbances that would confound the scientific rigor or interpretation of results of the study.
  • Have received an investigational drug within 30 days prior to screening or plan to receive an investigational drug (other than this gene therapy) during the study.
  • Currently participating in another interventional (drug/device) clinical trial.
  • Experienced an SAE (serious adverse event) related to scAAV9/JeT-GAN while participating in the first GAN IT study.
  • Contraindication to scAAV9/JeT-GAN or any of its ingredients.
  • Contraindication to any of the immune suppression medications used in this study.
  • Clinically significant abnormal laboratory values (GGT, ALT, and AST, or total bilirubin > 3 × ULN, creatinine ≥ 1.5 mg/dL, hemoglobin [Hgb] < 6 or > 20 g/dL; white blood cell [WBC] > 20,000 per cmm) prior to gene replacement therapy

Treatment and study plan

scAAv9/JeT-GAN

Genetic

The drug used in this study (scAAV9/JeT-GAN) has been studied in a previous gene therapy clinical trial by which the drug was administered as a single injection into the spinal canal (intrathecal [IT] administration) to treat the symptoms associated with the CNS and PNS neurodegeneration.

This is the first study in humans to administer the drug directly into the left vagus nerve.

Primary outcomes

  1. Safety of scAAV9/JeT-GAN when delivered to the Vagus Nerve - Based on the Number and Severity of Adverse Events Attributable to Toxicity

    Time frame: 3 years post treatment

    Safety and tolerability will be determine by the number of Incidences of unanticipated treatment-related toxicities, Grade 3 or higher. Toxicity of scAAV9/JeT-GAN i will be determined by the amount of occurrences and severity of serious adverse events (adverse events Grade 4 and 5).

    Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 details the criteria for classifying adverse events. The requirements for classifying an AE a Grade 3 or higher is the following:

    Grade 3 Severe: Severe or medically significant but not immediately life- threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self-care ADL (the ability to care for oneself without assistance).

    • Grade 4 Life-threatening consequences; urgent intervention indicated.
    • Grade 5 Death related to AE

Secondary outcomes

  1. Stability or Improvement in Autonomic Nervous Symptoms

    Time frame: 3 years post treatment

    Efficacy scAAV9/JeT-GAN will be determined by the stability or improvement in autonomic symptoms measured by the following Patient Reported Outcome Measures (PROM):

    • The COMPASS-31 is a scale used to measure neurodegenerative system symptoms related to autonomic dysfunction. A higher score indicates worse autonomic dysfunction.

    It consists of 31 patient-reported questions across six weighted domains.:

    • Orthostatic Intolerance (10 points): Assesses symptoms related to standing up, such as dizziness or fainting.
    • Vasomotor Symptoms (6 points): Evaluates issues like changes in skin color or temperature regulation.
    • Secretomotor Symptoms (7 points): Focuses on dryness of eyes and mouth.
    • Gastrointestinal Symptoms (28 points): Covers digestive issues.
    • Bladder Symptoms (9 points): Assesses urinary symptoms.
    • Pupillomotor Symptoms (15 points): Relates to pupillary function.

  2. Stability or Improvement of Motor Function

    Time frame: 2 Years

    The Motor Function Measurement-32 (MFM-32) is a clinician-reported outcome measure used to assess the functional abilities of individuals with neuromuscular diseases.

    The MFM32 assessment is comprised of 32 items that assess a range of different motor functional abilities across three functional domains:

    • Standing and transfers (D1: 13 items),
    • Axial and proximal motor function (D2: 12 items)
    • Distal motor function (D3: 7 items).

    These domains assess a broad spectrum of abilities including gross and distal motor functioning of the upper and lower limbs. Each MFM32 item is scored on a 4-point Likert scale from 0 (cannot initiate the task) to 3 (performs the task fully). Item scores are summed, and the raw score is transformed to an overall total score ranging from 0 (severe functional impairment) to 100 (no functional impairment).

Study contacts

Contact information is provided by the study sponsor or research team.

Kristy Riddle, BSN

CONTACT

[email protected]

214-456-9501

Samantha Bridges, BSN

CONTACT

[email protected]

214-456-3696

Sponsors and collaborators

Lead sponsor

University of Texas Southwestern Medical Center

Other

Registry information

Official study title

A Phase I/II Open-label Intraneural Administration of scAAV9/JeT-GAN Into the Vagus Nerve to Determine the Safety and Efficacy for Patients With Giant Axonal Neuropathy (GAN) Caused by a Mutation in the GAN Gene

Important dates

Study start
2026
Primary completion
2031
Study completion
2032
First posted
Apr 22, 2026
Registry last updated
Apr 22, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.